Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting

October 20, 2008

NEW HAVEN, Conn., Oct. 20 /PRNewswire/ — Rib-X Pharmaceuticals, Inc. (“Rib-X” or the “Company”), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that it will present a poster entitled “A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)” at the 2008 ICAAC/IDSA Joint Meeting in Washington, D.C. Details on the presentation are as follows:

          Poster Session:  New Treatment Options in Skin and Soft                           Tissue Infections          Poster Title:    A Phase 2 Study Comparing Two Doses of                           Radezolid to Linezolid in Adults with                           Uncomplicated Skin and Skin Structure                           Infections (uSSSI)          Date:            Sunday, October 26, 2008          Time:            12:15pm ET - 1:15pm ET          Location:        Hall C   

“We are extremely proud to have been selected to present at the leading global antimicrobials conference,” said Susan Froshauer, PhD, President and Chief Executive Officer, Rib-X Pharmaceuticals. “These data result from one of two proof-of-concept phase 2 trials with radezolid, a compound which derives from the Rib-X proprietary drug discovery approach. It is an honor to have our work recognized by the ICAAC/IDSA joint meeting organizers.”

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company’s integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X’s iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococci pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone resistant Gram positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at http://www.rib-x.com/.

Rib-X Pharmaceuticals, Inc.

CONTACT: Media: Irma Gomez-Dib, +1-212-850-5761, irma.gomez-dib@fd.com;Investors: John Capodanno, +1-212-850-5705, John.capodanno@fd.com, both of FDLife Sciences, for Rib-X Pharmaceuticals, Inc.

Web Site: http://www.rib-x.com/